主持或参加科研项目（课题）情况
1. 深圳市医学研究专项资金项目：腹腔镜术中增强现实导航设备研制与临床应用转化研究, D2402006. 2025.01- 2026. 12, 39.6万，共同主持人
2. 广东省卫健委2024年度卫生健康适宜技术推广项目：胆道可视化技术在预防腹腔镜胆囊切除术中胆道损伤的推广应用. 0万，主持人
3. 广东省卫健委2023年度卫生健康适宜技术推广项目：基于3DV Works 的可视化应用平台和系统在腹部外科疾病诊治中的应用. 0万，主持人
4. 2022广东省自然科学基金：靶向光动力治疗纳米载体Lins/Ce6@CaC03-PEG双重阻断糖酵解及氧化磷酸化能量代谢抑制胰腺癌生长的机制研究，2023A1515012906，2023.01-2026.01，10万，主持人。
5. 2023广东省自然科学基金：多级靶向纳米载体PEGPH20-SWNT@GEM@MK571逆转胰腺癌吉西他滨耐药的机制研究，2024A1515011531，2024.01-2027.01，15万，主持人。
6. 2021广州市科技计划项目：基于人工智能及三维可视化技术的肝胆疾病数字化诊疗平台构建及示范应用，202206010093。经费50万，主持人
7. 2021工信部卫健委联合”5G+医疗健康应用试点” 项目，面向医联体的5G+远程诊断系统研发及创新应用示范，2022.08-2025.08，300万，主持人
8. 2020广东省重点领域研发计划项目，2020B010165004，人机交互精准手术规划及实时引导软件关键技术，2020/01/01-2022/12/31,80万，参加，分题负责人
9. 2016广东省科技计划重大科技专项，2016B090917001，面向3D打印的数字医学技术支持中心建设及应用示范，资助金额：120万、分课题负责人
10. 2016国家科技部重点研发专项《分布式人类遗传资源库建设与应用示范》子课题《临床弃置资源回收规范流程及质量控制体系研究》，2016YFC1201802，2016/06-2018/12，39.6万，已结题，分题负责人
11. 2016广东省科技计划重大科技专项：2016B090917001,面向3D打印的数字医学技术支持中心建设及应用示范。2016/01/-2018/12, 120万，已结题，第3作者，分题负责人
12. 2015广东省科技计划重点项目，2015B031800091,基于无标记体表配准和肝脏有限元形变模型运动补偿的经皮肝穿刺导航研究，2015/10-2018/10,30万，已结题，主持
13. 2015广东省科技计划项目重大专项，2015B020214005，三维可视化技术联合3D腹腔镜精准肝切除手术导航系统的研制，2016/01- 2018/12, 100万，已结题，第2作者，分题负责人
获得学术奖励:
1.2015年 年度广东省科学技术奖二等奖《基于腹部CT图像后处理软件的三维重建图像在肝胆管结石诊断和治疗的应用研究，B15-0-2-03-R02》（第二完成人）
2.2014年 中国产学研合作创新成果奖《腹部医学单位可视化系统（MI-3DVS）,201411330》（第三完成人）
3.2010 年中华医学科技奖三等奖《数字医学技术在肝胆胰外科疾病诊断和治疗的临床研究，201003187PO803》(第三完成人)
4.2010 年度广东省科学技术奖一等奖《数字医学技术在肝胆胰外科疾病诊断和治疗的应用研究，B15-0-1-01-R05》(第五完成人)
代表性研究成果和学术奖励情况
（1） 非编码RNA及信号通路调控胰腺癌增殖、耐药
[1] Huang W#, Hu X, He X, Pan D, Huang Z, Gu Z, Huang G, Wang P*, Cui C*, Fan Y*. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Drug Resist Updat. 2024 May;74:101079. doi: 10.1016/j.drup.2024.101079.
[2] Gu J#,, Zhang J, Xia R, Wang X, Yang J, Xie F, Zhou Q, Li J, Zhang T, Chen Q, Fan Y*, Guo S*, Wang H*. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. Drug Resist Updat. 2024 Mar;73:101027. doi: 10.1016/j.drup.2023.101027.
[3] Gu J#, Huang W#, Wang X, Zhang J, Tao T, Zheng Y, Liu S, Yang J, Chen Z, Cai C, Li J,Wang H*, Fan Y*. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse Gemcitabine resistance in pancreatic cancer. Molecular Cancer, 2022, 21(1):112. ( IF:41.444)
[4] Huang W#, Gu J#, Tao T, Zhang J, Wang H*, Fan Y*. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation. Frontiers in oncology, 2019, 9:1499. (IF: 6.244)
[5] Gu J#, Huang W#, Zhang J, Wang X, Tao T, Yang L, Zheng Y, Liu S, Yang J, Zhu L, Wang H*, Fan Y*. TMPRSS4 promotes cell proliferation and inhibits apoptosis in pancreatic
ductal adenocarcinoma by activating ERK1/2 signaling pathway. Frontiers in oncology. 2021,11:628353. (IF: 6.244)
[6] Gu J#, Zhang J#, Huang W, Tao T, Huang Y, Yang L, Yang J, Fan Y*, Wang H*. Activating
miRNA-mRNA network in Gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4(+) T cells. Annals of translational medicine .2020, 8(6):279.(IF: 3.932)
[7] Zhang J#, Gu J#, Guo S, Huang W, Zheng Y, Wang X, Zhang T, Zhao W, Ni B*, Fan Y*, Wang H*. Establishing and validating a pathway prognostic signature in pancreatic cancer
based on miRNA and mRNA sets using GSVA. Aging, 2020,12(22):22840-22858. (IF: 5.682)
[8] Huang W#, Huang Y#, Gu J, Zhang J, Yang J, Liu S, Xie C, Fan Y*, Wang H*. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Am J Transl Res 2019,11:2983-94. (IF:4.06)
（2）胰腺癌的纳米药物合成及治疗
[1] Fan Y#, Shang WT#, Lu GH, Guo KX, Deng H, Zhu XH, Wang CC, Tian J*. Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer. Cancer Lett. 2021,S0304-3835(21)00463-8.（IF:8.679）
[2] Lu G#, Shang W#, Deng H, Han Z, Hu M, Liang X, Fang C, Zhu X, Fan Y*, Tian J*. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Biomaterials, 2019, 195: 13-22. （IF：10.273）
[3] Liang X#, Shang W#, Chi C, Zeng C, Wang K, Fang C, Chen Q, Liu H, Fan Y*, Tian J*. Dye-conjugated single-walled carbon nanotubes induce photothermal therapy under the guidance of near-infrared imaging[J]. Cancer Letters, 2016, 383(2): 243-249. (IF:6.491）
[4] Liu XY#, Wang JQ#, Ashby CR Jr, Zeng L, Fan YF*, Chen ZS*. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today. 2021 ,26(5):1284-1292. （IF:7.851）
[5] Zhu L#, Lin S#, Cui W, Xu Y, Wang L, Wang Z, Yuan S, Zhang Y*, Fan YF*, Geng J*. A nanomedicine enables synergistic chemo/photodynamic therapy for pancreatic cancer treatment. Biomater Sci. 2022, 10(13):3624-3636. （IF:7.59）
[6] Lu WL#, Kuang H, Gu J, Hu X, Chen B, Fan YF*,. GAP-43 targeted indocyanine green-loaded near-infrared fluorescent probe for real-time mapping of perineural invasion lesions in pancreatic cancer in vivo. Nanomedicine. 2023 Jun;50:102671. doi: 10.1016/j.nano.2023.102671. Epub 2023 Apr 11. PMID: 37054805.
（3）肿瘤化疗耐药及逆转耐药
[1] Fan Y#, Tao T#, Guo Z, Wah To KK, Chen D, Wu S, Yang C, Li J, Luo M, Wang F, Fu L*. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo. Mol Ther Oncolytics. 2022, 24:636-649. (IF:7.2）
[2] Fan Y#, Zhang W#, Zeng L, Lei ZN, Cai CY, Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS*, Trombetta LD*. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters, 2018, 421: 186-198.（IF:6.491）
[3] Narayanan S#，Fan YF#, Gujarati NA, Teng Q X,Wang, JQ，Cai, CY，Yang Y, Chintalapati AJ, Lei Y, Korlipara V*L, Chen ZS*. VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers, 2021, 13(19), 4917. （IF: 6.639）
[4] Zhang GN#, Gupta P#, Wang M, Barbuti AM, Ashby CR, Zhang YK, Zeng L, Xu Q, Fan YF*, Chen ZS*. Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers (Basel).2020 12(2):498. （IF:6.126）
[5] Wei LY#, Wu ZX#, Yang Y, Zhao M, Ma XY, Li JS, Yang DH, Chen ZS*, Fan Y*. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. Experimental Cell Research, 2020, 388(2):111858. (IF:3.383 )
[6] Wang JQ#, Wu ZX#, Yang Y, li JS, Yang DH, Fan YF*, Chen ZS*. Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Front. Oncol. 2021,11:731260. ( IF:6.244)
[7] Wang JQ#, Teng QX#, Lei ZN, Ji N, Cui Q, Fu H, Lin L, Yang DH, Fan YF*, Chen ZS*. Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Front Cell Dev Biol. 2020, 8:601400. (IF: 5.206）
[8] Lei ZN#, Teng QX#, Gupta P, Zhang W, Narayanan S, Yang DH, Wurpel JND, Fan YF*, Chen ZS*. Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. Front Cell Dev Biol. 2021,9:640957.（IF:5.206）
[9] Li YD#, Mao Y#, Dong XD, Lei ZN, Yang Y, Lin L, Ashby CR Jr, Yang DH, Fan YF*, Chen ZS*. Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. Front Oncol. 2020,10:932. （IF:4.137）
[10] Zhang W#, Fan YF#, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P*, Chen ZS*. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells, Frontiers in pharmacology,2018,9:1097.（IF:3.845）
[11] Liu XY#, Wang JQ#, Ashby CR Jr, Zeng L, Fan YF*, Chen ZS*. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today. 2021 ,26(5):1284-1292. （IF=7.851）
4.医学图像分割重建及三维可视化及影像组学
[1] Cai W#, He B#, Fan Y*,Fang C,Jia F*. Comparison of liver volumetry on contrast‐enhanced CT images: one semiautomatic and two automatic approaches. Journal of Applied Clinical Medical Physics, 2016, 17(6): 118～127. （IF=1.30）
[2] Cai W#, Fan Y#, Hu H, Xiang N, Fang C*, Jia F*. Postoperative liver volume was accurately predicted by a medical image three dimensional visualization system in hepatectomy for liver cancer. Surgical Oncology, 2017, 26(2): 188～194. （IF= 3.279）
[3] Zhang Q#, Fan Y*, Wan J, Liu Y*. An Efficient and Clinical-Oriented 3D Liver Segmentation Method[J]. IEEE Access, 2017, 5: 18737～18744. （IF=4.098）
[4] Xiaojun Hu, Changfeng Li, Qiang Wang, Xueyun Wu, Zhiyu Chen, Feng Xia, Ping Cai, Leida Zhang, Yingfang Fan, Kuansheng Ma. Development and external validation of a radiomics model derived from preoperative gadoxetic Acid-Enhanced MRI for predicting histopathologic grade of hepatocellular carcinoma[J]. Diagnostics (Basel), 2023, 13(3).（IF：3.992）
[5] Xiaojun Hu, Qiang Wang, Guobing Huang, Xiang He, Ernesto Sparrelid, Torkel B Brismar, Yingfang Fan [J]. Comput Math Methods Med, 2023, 2023: 5424204. （IF：2.809）
[6] Qiang Wang, Changfeng Li, Jiaxing Zhang, Xiaojun Hu , Yingfang Fan , Kuansheng Ma , Ernesto Sparrelid, Torkel B Brismar . Radiomics models for predicting microvascular invasion in hepatocellular carcinoma: A systematic review and radiomics quality score assessment[J]. Cancers (Basel), 2021, 13(22).（IF：6.575）
合作文章
[1] Teng QX, Ashar YV, Gupta P, Gadee E, Fan YF, Reznik SE, Wurpel JND, Chen ZS. Revisiting mTOR inhibitors as anticancer agents. Drug Discov Today. 2019 Oct;24(10):2086-2095. doi: 10.1016/j.drudis.2019.05.030. Epub 2019 Jun 4. PMID: 31173912. IF:7.088
[2] Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9. PMID: 31078601. IF:6.100
[3] Wen Y, Zhao R, Gupta P, Fan Y, Zhang Y, Huang Z, Li X, Su Y, Liao L, Xie YA, Yang D, Chen ZS, Liang G. The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo. Acta Pharm Sin B. 2019, 9(2):316-323. doi: 10.1016/j.apsb.2018.10.001. Epub 2018 Oct 12. PMID: 30972279; PMCID: PMC6437594. IF:14.903
[4] Lee SB, Kim JJ, Han SA, Fan Y, Guo LS, Aziz K, Nowsheen S, Kim SS, Park SY, Luo Q, Chung JO, Choi SI, Aziz A, Yin P, Tong SY, Fiesel FC, Springer W, Zhang JS, Lou Z. The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome. Nat Cell Biol. 2019 Aug;21(8):940-951. doi: 10.1038/s41556-019-0356-8. Epub 2019 Jul 29. PMID: 31358971; PMCID: PMC6679774. IF:28.213
授权发明专利:
1.贾富仓，黄成，罗火灵，张晓东，方驰华，范应方,胡庆茂，一种CT图像肝脏分割的处理方法及系统，2015-12-23，中国，ZL201210571829.8
2.罗火灵，贾富仓，方驰华，范应方，项楠，胡庆茂，一种标记点配准方法、装置及外科手术导航系统，2017-10-03，中国，ZL201210538735.0
3.贾富仓，肖德强，罗火灵，胡庆茂，方驰华，范应方，一种穿刺规划路径纠正方法及装置，2017-07-14，中国，ZL201510816045.5
4.贾富仓，李媛，方驰华，范应方，项楠，张晓东，罗火灵，胡庆茂，一种多图谱融合方法、系统及医疗设备，2016-04-06，中国,ZL201210580483.8
5.罗火灵，肖德强，贾富仓，方驰华，范应方，一种腹部外科手术导航方法及系统，2019-03-01，中国，ZL201310436801.8
6.贾富仓，李雯，贺宝春，胡庆茂，方驰华，范应方，一种基于CT图像的肝脏肿瘤分割方法及装置，2018-08-21,中国，ZL201510925624.9